ANALYSIS: As Vital Healthcare revives a restructuring scheme, directors of its external manager seem particularly antsy about their independence.
With just nine days to go until Christmas, Hunter’s Corner cuts to the chase.
OPINION: The process of privatising perennial penny dreadful Seadragon has been almost surgical.
ANALYSIS: Amid rumours of buyers walking away from a billion-dollar deal on its metering business, Vector’s bargaining position appears to have shifted.
ANALYSIS: But with investors under water from this year's capital raise, acquisition of Quay Street not necessarily a crowd pleaser.
OPINION: The instinct for self-preservation is strong in NZ Growth Capital Partners.
ANALYSIS: A review of five years of monetary policy is big on information, but perception also has a part to play.
ANALYSIS: Buyout offer for listed fintech has attracted arbitrage trade but, for investors looking beyond the short term, it’s far from a done deal.
ANALYSIS: The A1-free milk niche is attracting some strange competitors.
ANALYSIS: An Infratil unit is double-teaming with its ASX-listed counterpart to challenge investment from clinicians.
